Eagle Pharmaceuticals Announces 2025 Annual Meeting Date

Rhea-AI Summary

Eagle Pharmaceuticals (OTCMKTS: EGRX) has announced its 2025 Annual Meeting of Stockholders will be held on October 17, 2025. The company has set August 18, 2025 at 5 p.m. Eastern Time as the record date for stockholder participation. Specific details regarding the meeting time and location will be communicated directly to eligible stockholders through official meeting materials.

News Market Reaction – EGRX

-0.63%

-0.63% Session close to close

In the Aug 19 session, EGRX declined 0.63%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WOODCLIFF LAKE, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) will be held on October 17, 2025. The specific time and place for the 2025 Annual Meeting will be specified in a notice and meeting materials to be provided to stockholders of record as of 5 p.m. Eastern Time on August 18, 2025, which is the record date for the meeting.

The Company’s bylaws establish certain procedural requirements and deadlines that are applicable to annual stockholder meetings, including the 2025 Annual Meeting. A copy of the bylaws can be found at the following link: Eagle Bylaws.

About Eagle Pharmaceuticals, Inc.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care.

Investor Relations Contact

Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com

FAQ

When is Eagle Pharmaceuticals (EGRX) 2025 Annual Meeting?

Eagle Pharmaceuticals' 2025 Annual Meeting of Stockholders will be held on October 17, 2025. The specific time and location will be announced in the meeting materials.

What is the record date for Eagle Pharmaceuticals' 2025 Annual Meeting?

The record date is August 18, 2025 at 5 p.m. Eastern Time. Stockholders of record as of this date will be eligible to participate in the annual meeting.

How can stockholders access Eagle Pharmaceuticals' meeting materials?

Meeting materials, including the specific time and location, will be provided directly to stockholders of record. The company's bylaws containing procedural requirements can be accessed through the Eagle Bylaws link.

Where can investors find Eagle Pharmaceuticals' bylaws for the annual meeting?

Eagle Pharmaceuticals' bylaws, which contain the procedural requirements for annual stockholder meetings, can be accessed through the Eagle Bylaws link provided by the company.